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Abstract
Background: The aim of the study was to assess the association between antihypertensive therapy and the manifesta-
tions of insomnia in patients with arterial hypertension (AH) and type 2 diabetes mellitus (T2DM).
Material and methods: The study included 120 hypertensive patients with and without T2DM (among them there 
were 60 patients with insomnia). The study consisted of three stages. The first stage was conducted as a cross-sectional 
study, during which an association was established between different antihypertensive products and the presence of 
insomnia in the study population. The second and third stages were a prospective study, during which a modification 
of the therapy to reduce the manifestations of insomnia was performed.
Results: It was found that patients receiving amlodipine in the combination antihypertensive therapy had insomnia 
manifestations much less frequently as compared to indapamide. A statically significant decrease in blood pressure 
(BP) and a higher proportion of patients with target BP were observed in both groups. Replacement of indapamide 
with amlodipine was shown to improve sleep quality. Thus, the number of patients with insomnia significantly 
decreased in both groups. After correction of antihypertensive therapy after 12 months, all patients were assessed 
for sleep disorders. The incidence of insomnia was found to be significantly reduced in both groups after changing 
therapy from indapamide to amlodipine.
Conclusions: Correction of antihypertensive therapy, namely the replacement of indapamide with amlodipine, 
contributes to an improvement in BP, quality of life, and a reduction in the proportion of patients with insomnia.
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Introduction
The association between insomnia and cardiovascular 
diseases has been proven in a large number of works 
[1–4]. According to Taylor [5], 40% of patients with 
diseases of the cardiovascular system have problems 
with the quality or duration of sleep. A high preva-
lence of insomnia among patients with hypertension 
and its effect on the course of hypertension was dem-
onstrated in a systemic review of Jarrin [6]. Li [7] 
found that difficulties in maintaining sleep and early 
morning awakenings significantly increased the risk 
of developing hypertension. Fernamdez-Mendoza 
[8] confidently demonstrated that insomnia was an 
independent risk factor for developing hypertension. 
A higher risk of developing hypertension in people 
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with insomnia was also found in study of Lin [9]. 
For instance, according to these authors, patients 
with insomnia have a 21% higher risk of developing 
hypertension compared with those who have quality 
sleep [9]. At the same time, Wang [10] found that 
insomnia is much more common in patients with 
hypertension (36.35%) compared with the general 
population (28.9%). Similar data were presented in 
a study of Bathgate [11], who found that almost 
36.9% of patients with hypertension had some form 
of insomnia. A study, which included 21.678 pa-
tients with a medical history of stroke, demonstrated 
that those with hypertension were more likely to take 
sleeping pills [12]. The presented literature data show 
that insomnia is both a risk factor for hypertension 
and often accompanies it. It should be noted that 
a patient with both diseases can live quite a long time 
and there is a problem of finding the optimal therapy 
for this group of patients.
At the same time, data on the effect of antihyper-
tensive therapy on the quality and duration of sleep 
are scarcely presented in the modern literature.
The aim of the study was to assess the association 
between antihypertensive therapy and the manifesta-
tions of insomnia in patients with hypertension and 
type 2 diabetes mellitus.
Material and methods
General characteristics and design of the study 
The study consisted of three stages. The first stage 
was conducted as a cross-sectional study, during 
which an association was established between dif-
ferent antihypertensive products and the presence of 
insomnia in the study population. The second and 
third stages were a prospective study, during which 
a modification of the therapy to reduce the manifes-
tations of insomnia was performed. The study design 
is presented in Figure 1.
The inclusion criteria were age over 45 years, pres-
ence of hypertension. The diagnosis of hypertension 
was established according to the 2018 ESC/ESH 
Guidelines for the management of arterial hyperten-
sion [13]. The diagnosis of type 2 diabetes mellitus 
was established according to the Unified Clinical 
Protocol of Primary and Secondary (Specialized) 
Medical Care: Type 2 Diabetes (Order of the Minis-
try of Health No. 1118 of 21.12.2012) [14].
The study did not include patients who had car-
diovascular events (myocardial infarction, stroke), 
patients with heart failure or with an ejection frac-
tion of less than 45%, with resistant arterial hy-
pertension, thyroid gland dysfunction, gastric ulcer 
and duodenal ulcer in the exacerbation phase, with 
concomitant diseases affecting the quality of life, pa-
tients with obesity grade III, with concomitant any 
active cancer, with depressive states (organic depres-
sive disorder (F 06.32), recurrent depressive disorder 
(F 33.0–3) or a depressive episode of any severity 
(F 31.3–5, F 32.0–3), also a mixed anxiety and de-
pressive disorder (F 41.2) according to the criteria 
of the International Classification of Diseases 10th 
revision (ICD-10), with insomnia as a symptom of 
any mental illness, with concomitant therapy with 
glucocorticosteroids, antihypertensive drugs of cen-
tral action (moxonidine, reserpine), beta-blockers, 
hypnotics, patients who confirmed eating at night, 
patients with obstructive sleep apnea syndrome.
During stage 2, all patients, who were diag-
nosed with sleep disorders, were enrolled in “Health 
Schools” for 3 months, after which the following 
were assessed: sleep disorders, quality of life, an-
thropometric, hemodynamic, and biochemical pa-
rameters. After finishing the “Health Schools”, there 
were 56 patients with symptoms of insomnia in the 
general group, among whom 36 patients had com-
bined hypertension and type 2 diabetes mellitus, and 
20 of them had isolated hypertension. A detailed 
analysis of the antihypertensive therapy showed that 
in the group of combined hypertension and diabetes 
mellitus with insomnia symptoms, indapamide was 
taken by 78% of patients, while amlodipine by 22% 
(p = 0.05). The same trend was observed in the group 
of isolated hypertension with insomnia: indapamide 
was taken by 70.6% of patients, while amlodipine by 
29.4% (p = 0.05). Due to the fact that insomnia was 
less common among patients in both groups receiv-
ing amlodipine, indapamide therapy was replaced 
by amlodipine. Patients received this therapy for 12 
months. Then, sleep disorders, quality of life index, 
hemodynamic parameters were re-assessed and the 
percentage of patients who reached the target blood 
pressure was calculated (Fig. 1).
Assessment of sleep disorders
The presence of insomnia was assessed using the 
criteria of the International Classification of Sleep 
Disorders, 3rd Edition, which was developed by the 
International Academy of Sleep Disorders, 2014 
[15]. The diagnosis of insomnia was established in 
the presence of the following criteria: 1 — diffi-
culty falling asleep or staying asleep continuously; 
2 — availability of adequate sleeping conditions; 
3 — day consequences of poor sleep quality [15]. 
The night apnea syndrome was detected by night 
monitoring with the use of a SOMNOcheck micro 
CARDIO device (2013, Germany).
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Figure 1. Design of the study. * «+» Insomnia is present; «–» Insomnia is absent. T2DM — type 2 diabetes mellitus
Subjects with hypertension and hypertension + T2DM
according to inclusion/exclusion criteria 
(n = 120)*
Assessment of insomnia
(using the criteria of the International Classication of Sleep 
Disorders, Issue 3) 
Insomnia «–» 
(n = 60) 
Insomnia «+» 
(n = 60) 
Hypertension 
+ T2DM
(n = 39) 
Hypertension 
(n = 21) 
Hypertension 




Assessment of the 
composition of therapy by 
drugs and doses 
«Schools» for patients 
(n = 60) 
Insomnia «+» 
 (n = 56) 
Insomnia «–» 
(n = 4) 
Replacement of indapamide therapy
with amlodipine 
Assessment of insomnia























































(n = 20) 
Ganna Isayeva et al. Chronic insomnia in arterial hypertension and type 2 diabetes
195www.ah.viamedica.pl
Instrumental examination
Blood pressure was measured in accordance with the 
current recommendations of the European Society of 
Cardiology [13].
Assessment of achievement of target indicators
Achievement of target blood pressure levels and lipid 
metabolism values was assessed in accordance with 
current recommendations of the European Society of 
Cardiology [13].
Therapy
Patients were initially treated with an ACE inhibi-
tor (ramipril) or sartan (valsartan), a diuretic (in-
dapamide) and a calcium antagonist (amlodipine). 
All patients received atorvastatin as a lipid-lowering 
therapy and metformin as an antidiabetic therapy.
Statistical data processing
Statistical analysis was performed with the use of 
SPSS, version 17.0 (Chicago, IL. USA). The type of 
data distribution was assessed using the Kolmogorov-
Smirnov method. With the normal distribution of 
continuous values, the data are presented as mean 
values (M) and standard deviation (SD), for quanti-
tative values — the number (n) and frequency (%). 
Data which did not meet the requirements of normal 
distribution were presented as medians and 25% 
and 75% quartiles. The Student’s t-test was used for 
comparing two independent samples corresponding 
to normal distribution. If the dependent samples did 
not meet the requirements of normal distribution, 
the comparison was performed using the Mann-
Whitney test. Differences were considered as statisti-
cally significant if p < 0.05.
Ethic aspects
The study was approved by the Commission on Eth-
ics and Deontology of the State Institution “L.T. 
Malaya National Institute of Therapy of the National 
Academy of Medical Sciences of Ukraine” on April 
28, 2017. All participants of the study signed an in-
formed consent, the aim and objectives of the study 
were previously clearly explained to them.
Results 
Patients receiving amlodipine were found to have in-
somnia manifestations much less frequently (Fig. 2).
The therapy in groups after replacement of indap-
amide with amlodipine is shown in Figure 3.
A statically significant decrease in blood pressure 
(Tab. 1) and a higher proportion of patients with 
target blood pressure were observed in both groups 
(Fig. 4 and 5).
Replacement of indapamide with amlodipine was 
shown to improve sleep quality. Thus, the number 
of patients with insomnia significantly decreased in 
both groups.
After correction of antihypertensive therapy after 12 
months, all patients were assessed for sleep disorders. 
The incidence of insomnia was found to be signifi-
cantly reduced in both groups after changing therapy 
from indapamide to amlodipine (p = 0.05) (Fig. 7).
Discussion
Although insomnia is quite common in patients with 
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Figure 2. Medical therapy in groups with and without insomnia. A. Patients with hypertension + diabetes mellitus type 2. B. Patients with 
hypertension. Data presented as a proportion of patients (%) treated with particular drug
A B
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Table 1. Dynamics of hemodynamic parameters of patients in groups with symptoms of insomnia before and after correction of therapy*
Index
Group 1 (hypertension + T2DM)  
(n = 36)
Group 2 (hypertension) 
(n = 20)
1 stage 2 stage 3 stage p 1 stage 2 stage 3 stage p
SBP  


























T2DM — type 2 diabetes mellitus; SBP — systolic blood pressure; DBP — diastolic blood pressure. *Data presented in the view of the middle value and the standard deviation (M ± s)
Figure 3. Medical therapy during third period of study (after replacement of indapamid to amlodipine). A. Patients with hypertension 












Figure 4. Number of patients with target systolic blood pressure (SBP) and diastolic blood pressure (DBP) in patients with hypertension 
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there are very little data in the literature on the causes 
for the development of such a sleep disorder in this 
group of patients.
Certainly, the development of insomnia in pa-
tients with hypertension and type 2 diabetes mellitus 
is based on several general mechanisms of pathogen-
esis. First of all, the possible activation of the sympa-
thoadrenal system underlying both the pathogenesis 
of hypertension and always accompanying insomnia 
should be taken into account [16, 17]. Markers of 
systemic inflammation were found to increase both in 
chronic insomnia as well as in hypertension and type 
2 diabetes mellitus. An increase in the production 
and release of aldosterone was found in patients with 
insomnia. Also, there are studies demonstrating en-
dothelial dysfunction in chronic sleep disorders. An 
important factor contributing to the development of 
insomnia in patients with hypertension and diabetes 
mellitus is increased anxiety and depression, which 
also often accompany both conditions. Certainly, the 
most interesting for the practicing physician is the 
question: can antihypertensive therapy contribute 
to the development of insomnia or, on the contrary, 
reduce the risk of this condition. When searching 
the PubMed, Clinicaltrials.org, MedLine, SCOPUS 
databases, we did not find clinical randomized trials 
that take into account the risk of developing in-
somnia in hypertensive patients under the influence 
of antihypertensive therapy. Quite interesting is the 
paper of Tanabe [18], which is a pharmacoeconomic 
study. The authors demonstrated that the risk of 
developing insomnia in patients with hypertension 
is increased in the highest degree by therapy with 
alpha- and beta-blockers. So, according to the study 
by Tanabe [18] the risk of developing insomnia with 
the administration of alpha-blockers was OR = 2.38; 
Figure 6. The proportion of patients with insomnia in the groups of combined hypertension with type 2 diabetes mellitus and isolated 
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95% confidence interval (CI): 1.14–4.98, and in the 
case of b-blockers — OR = 1.54; 95% CI: 0.99–2.39. 
In comparison, the risk of developing insomnia 
with calcium antagonist therapy was 0.67; 95% CI: 
0.47–0.96. ACE inhibitor therapy was not associated 
with the risk of developing insomnia. According to 
the authors’ data, insomnia, as a rule, manifested 
itself by the 5th week of therapy and in more than 
50% of cases manifested itself as “difficulty falling 
asleep” [18]. A study by Chang [19] also confirmed 
the ability of beta b-blockers to induce insomnia and 
this effect depended on the degree of b(1)-receptor 
selectivity and lipophilicity of the drug. Interesting 
results are presented by Finnish scientists. Haaramo 
[20] showed that antihypertensive therapy could 
contribute to the development of insomnia symp-
toms: OR = 1.57, 95% CI: 1.23–2.00. John W Win-
kelman [21] demonstrated that diuretic therapy can 
negatively affect sleep quality. There are also data 
in literature, which demonstrates an increase in the 
risk of developing insomnia in the case of using 
ACE inhibitors through the possibility of developing 
such an adverse effect as a cough [22]. Nevertheless, 
the described works are non-systemic and are not 
prospective studies. Although the abovementioned 
literature data confirm the presence of a connection 
between antihypertensive therapy and the risk of 
developing insomnia, our results demonstrate that 
the risk of developing insomnia can be reduced by 
replacing the diuretic indapamide with amlodipine. 
Our study was conducted as a prospective one with 
a quite long follow-up period — 12 months.
It should be noted that a decrease in insomnia 
itself contributes to a decrease in blood pressure [11, 
23]. Therefore, a search for relationships between 
antihypertensive therapy and the risk of developing 
sleep disorders will allow developing an individu-
alized approach to patients with hypertension and 
insomnia.
Conclusion
Correction of antihypertensive therapy, namely the 
replacement of indapamide with amlodipine, con-
tributes to an improvement in blood pressure, qual-
ity of life, and a reduction in the proportion of 
patients with insomnia.
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